Organogenesis Holdings Inc. is a leading regenerative medicine company offering a portfolio of bioactive and acellular biomaterials products in advanced wound care and surgical biologics, including orthopedics and spine. Organogenesis's comprehensive portfolio is designed to treat a variety of patients with repair and regenerative needs.
Company profile
Ticker
ORGO
Exchange
Website
CEO
Gary S. Gillheeney
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Avista Healthcare Public Acquisition Corp.
SEC CIK
Corporate docs
Subsidiaries
Organogenesis Inc. • Prime Merger Sub, LLC • Organogenesis Switzerland GmbH ...
ORGO stock data
Latest filings (excl ownership)
S-8
Registration of securities for employees
9 Dec 22
10-Q
2022 Q3
Quarterly report
9 Nov 22
8-K
Organogenesis Holdings Inc. Reports Third Quarter 2022 Financial Results
9 Nov 22
10-Q
2022 Q2
Quarterly report
9 Aug 22
8-K
Organogenesis Holdings Inc. Reports Second Quarter 2022 Financial Results
9 Aug 22
8-K
Material Modifications to Rights of Security Holders
27 Jun 22
10-Q
2022 Q1
Quarterly report
10 May 22
DEF 14A
Definitive proxy
10 May 22
8-K
Organogenesis Holdings Inc. Reports First Quarter 2022 Financial Results
10 May 22
8-K
Organogenesis Appoints Michele Korfin and Gilberto Quintero, Ph.D. to Board of Directors
5 May 22
Transcripts
ORGO
Earnings call transcript
2022 Q3
10 Nov 22
ORGO
Earnings call transcript
2022 Q2
9 Aug 22
ORGO
Earnings call transcript
2022 Q1
11 May 22
ORGO
Earnings call transcript
2021 Q4
2 Mar 22
ORGO
Earnings call transcript
2021 Q3
10 Nov 21
ORGO
Earnings call transcript
2021 Q2
10 Aug 21
ORGO
Earnings call transcript
2021 Q1
11 May 21
ORGO
Earnings call transcript
2020 Q4
17 Mar 21
ORGO
Earnings call transcript
2020 Q3
9 Nov 20
ORGO
Earnings call transcript
2020 Q2
11 Aug 20
Latest ownership filings
Financial summary
| Quarter (USD) | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 108.02 mm | 108.02 mm | 108.02 mm | 108.02 mm | 108.02 mm | 108.02 mm |
| Cash burn (monthly) | 1.64 mm | (no burn) | (no burn) | (no burn) | (no burn) | (no burn) |
| Cash used (since last report) | 6.77 mm | n/a | n/a | n/a | n/a | n/a |
| Cash remaining | 101.26 mm | n/a | n/a | n/a | n/a | n/a |
| Runway (months of cash) | 61.7 | n/a | n/a | n/a | n/a | n/a |
Institutional ownership, Q3 2022
55.1% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 149 |
| Opened positions | 26 |
| Closed positions | 24 |
| Increased positions | 70 |
| Reduced positions | 31 |
| 13F shares | Current |
|---|---|
| Total value | 349.27 mm |
| Total shares | 72.11 mm |
| Total puts | 0.00 |
| Total calls | 39.30 k |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| Ades Alan A. | 10.76 mm | $99.76 mm |
| BLK Blackrock | 10.54 mm | $34.14 mm |
| Flynn James E | 8.46 mm | $78.14 mm |
| Soleus Capital Management | 6.49 mm | $21.03 mm |
| Vanguard | 4.48 mm | $14.51 mm |
| MS Morgan Stanley | 3.25 mm | $10.54 mm |
| FHI Federated Hermes | 2.60 mm | $8.43 mm |
| Assenagon Asset Management | 2.01 mm | $6.51 mm |
| Millennium Management | 1.50 mm | $4.85 mm |
| Geode Capital Management | 1.31 mm | $4.26 mm |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 21 Nov 22 | Michael W Katz | Class A Common Stock | Buy | Acquire P | No | No | 2.56 | 3,000 | 7.68 k | 76,382 |
| 18 Nov 22 | Michael W Katz | Class A Common Stock | Buy | Acquire P | No | No | 2.57 | 3,000 | 7.71 k | 73,382 |
| 20 Aug 22 | Grow Brian | Class A Common Stock | Option exercise | Acquire M | No | No | 1.46 | 805 | 1.18 k | 87,744 |
| 20 Aug 22 | Grow Brian | Stock Option Class A Common Stock | Option exercise | Dispose M | No | No | 1.46 | 805 | 1.18 k | 0 |
| 12 Aug 22 | Michael Joseph Driscoll | Class A Common Stock | Buy | Acquire P | No | No | 4.8 | 5,000 | 24.00 k | 25,547 |
| 12 Aug 22 | Leibowitz Arthur S | Class A Common Stock | Buy | Acquire P | No | No | 4.755 | 3,000 | 14.27 k | 70,854 |
| 30 Jun 22 | Gillheeney Gary S. | Class A Common Stock | Option exercise | Acquire M | No | No | 0.99 | 505,050 | 500.00 k | 903,292 |
| 30 Jun 22 | Gillheeney Gary S. | Stock Option Class A Common Stock | Option exercise | Dispose M | No | No | 0.99 | 505,050 | 500.00 k | 0 |
News
5 Value Stocks In The Healthcare Sector
30 Jan 23
Looking Into Organogenesis Holdings's Return On Capital Employed
15 Dec 22
Why Apyx Medical Shares Dipped Over 60%; Here Are 123 Biggest Movers From Yesterday
11 Nov 22
12 Health Care Stocks Moving In Thursday's Intraday Session
10 Nov 22
Why Magnite Shares Are Trading Higher By Over 45%? Here Are 69 Stocks Moving In Thursday's Mid-Day Session
10 Nov 22
Press releases
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Organogenesis Holdings Inc.
19 Jan 23
Organogenesis Holdings Inc. to Participate in the Cantor Fitzgerald Medical and Aesthetic Dermatology, Ophthalmology and Medtech Conference
5 Dec 22
Lifshitz Law PLLC Announces Investigations of Sleep Number Corporation (NASDAQ: SNBR), Organogenesis Holdings, Inc. (NASDAQ: ORGO), Netflix Inc. (NASDAQ: NFLX), and Mullen Automotive Inc. (NASDAQ: MULN)
19 Nov 22